Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
April 18, 2007

Avanir’s Value More Than Doubled on Phase III Results of Diabetic Neuropathic Pain Drug

  • Avanir Pharmaceuticals reported positive results from the Phase III evaluation of its diabetic neuropathic pain drug. The company’s shares soared 165% to open trading at $3.37.

    Zenvia (dextromethorphan hydrobromide/quinidine sulfate (DMQ)) is an NMDA antagonist and sigma-1 agonist. In the trial, two doses of Zenvia, 45/30 mg DMQ and 30/30 mg DMQ, both dosed twice daily, were compared to placebo. Both treatment groups had lower pain ratings than placebo patients. The drug also showed statistically significant improvements in a number of secondary endpoints, including pain relief and pain intensity.

    Zenvia is also in development for the treatment of involuntary emotional expression disorder.

  • You’re all set! Thank you for subscribing to GEN Highlights.